Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Zegalogue
1. 1544300-84-6
2. Dasiglucagon [inn]
3. Dasiglucagon [usan]
4. Dasiglucagon [who-dd]
5. Dasiglucagon [usan:inn]
6. Unii-ad4j2o47fq
7. Ad4j2o47fq
8. Zp-ga-1
9. Dtxsid501336774
10. Zp4207
11. Zp-4207
12. His-ser-gln-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-aib-ala-arg-ala-glu-glu-phe-val-lys-trp-leu-glu-ser-thr
13. L-threonine, L-histidyl-l-seryl-l-glutaminylglycyl-l-threonyl-l-phenylalanyl-l-threonyl-l-seryl-l-alpha-aspartyl-l-tyrosyl-l-seryl-l-lysyl-l-tyrosyl-l-leucyl-l-alpha-aspartyl-2-methylalanyl-l-alanyl-l-arginyl-l-alanyl-l-alpha-glutamyl-l-alpha
Molecular Weight | 3381.6 g/mol |
---|---|
Molecular Formula | C152H222N38O50 |
XLogP3 | -15.9 |
Hydrogen Bond Donor Count | 52 |
Hydrogen Bond Acceptor Count | 55 |
Rotatable Bond Count | 110 |
Exact Mass | 3380.6030550 g/mol |
Monoisotopic Mass | 3379.5997002 g/mol |
Topological Polar Surface Area | 1450 Ų |
Heavy Atom Count | 240 |
Formal Charge | 0 |
Complexity | 7900 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 30 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Treatment of hypoglycaemia
Dasiglucagon works to increase blood glucose levels under normal and hypoglycemic conditions. After administration of dasiglucagon in adult patients with type 1 diabetes, the mean glucose increase from baseline at 90 minutes was 168 mg/dL. In pediatric patients with type 1 diabetes aged seven to 17 years, the mean glucose increase at 60 minutes after administration of dasiglucagon was 162 mg/dL.
Absorption
Following subcutaneous administration of 0.6 mg dasiglucagon, the mean peak plasma concentration was 5110 pg/mL (1510 pmol/L). Tmax was 35 minutes. In pediatric patients with type 1 diabetes, the mean peak plasma concentration of 3920 pg/mL occurred at around 21 minutes. Dasiglucagon has a higher absorption rate than traditional reconstituted glucagon.
Volume of Distribution
The mean apparent volume of distribution ranged from 47 L to 57 L after subcutaneous administration.
Like endogenous glucagon, dasiglucagon undergoes proteolytic degradation pathways in blood, liver, and kidney.
The half-life was approximately 30 minutes following subcutaneous administration. Dasiglucagon has a longer plasma elimination half-life than traditional reconstituted glucagon.
Dasiglucagon is an analog of glucagon, which is a peptide hormone responsible for increasing blood glucose levels. It has the same mechanism of action as endogenous glucagon by acting as an agonist at glucagon receptors, which are G-coupled receptors expressed throughout the body. Dasiglucagon binds to glucagon receptors in the liver, which activates Gs and Gq, and consequently, adenylate cyclase. Adenyl cyclase increases intracellular cyclic AMP, which stimulates glycogenolysis and glucogenesis in the liver. As glucose is primarily released from liver glycogen stores, hepatic stores of glycogen are crucial for dasiglucagon to exert its antihypoglycemic effects.
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34276
Submission : 2019-11-21
Status : Active
Type : II
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34276
Submission : 2019-11-21
Status : Active
Type : II
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Dasiglucagon manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dasiglucagon, including repackagers and relabelers. The FDA regulates Dasiglucagon manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dasiglucagon API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dasiglucagon supplier is an individual or a company that provides Dasiglucagon active pharmaceutical ingredient (API) or Dasiglucagon finished formulations upon request. The Dasiglucagon suppliers may include Dasiglucagon API manufacturers, exporters, distributors and traders.
click here to find a list of Dasiglucagon suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dasiglucagon DMF (Drug Master File) is a document detailing the whole manufacturing process of Dasiglucagon active pharmaceutical ingredient (API) in detail. Different forms of Dasiglucagon DMFs exist exist since differing nations have different regulations, such as Dasiglucagon USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dasiglucagon DMF submitted to regulatory agencies in the US is known as a USDMF. Dasiglucagon USDMF includes data on Dasiglucagon's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dasiglucagon USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dasiglucagon suppliers with USDMF on PharmaCompass.
Dasiglucagon Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dasiglucagon GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dasiglucagon GMP manufacturer or Dasiglucagon GMP API supplier for your needs.
A Dasiglucagon CoA (Certificate of Analysis) is a formal document that attests to Dasiglucagon's compliance with Dasiglucagon specifications and serves as a tool for batch-level quality control.
Dasiglucagon CoA mostly includes findings from lab analyses of a specific batch. For each Dasiglucagon CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dasiglucagon may be tested according to a variety of international standards, such as European Pharmacopoeia (Dasiglucagon EP), Dasiglucagon JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dasiglucagon USP).
LOOKING FOR A SUPPLIER?